nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—CYP2C8—Nilutamide—prostate cancer	0.136	0.282	CbGbCtD
Tazarotene—CYP2C8—Abiraterone—prostate cancer	0.113	0.234	CbGbCtD
Tazarotene—CYP2C8—Cabazitaxel—prostate cancer	0.0836	0.173	CbGbCtD
Tazarotene—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0728	0.151	CbGbCtD
Tazarotene—CYP2C8—Estradiol—prostate cancer	0.0469	0.0971	CbGbCtD
Tazarotene—CYP2C8—Etoposide—prostate cancer	0.0306	0.0634	CbGbCtD
Tazarotene—RARB—prostate gland—prostate cancer	0.00682	0.158	CbGeAlD
Tazarotene—RARG—prostate gland—prostate cancer	0.00556	0.129	CbGeAlD
Tazarotene—Hypertriglyceridaemia—Abiraterone—prostate cancer	0.00545	0.0263	CcSEcCtD
Tazarotene—RARA—prostate gland—prostate cancer	0.00523	0.121	CbGeAlD
Tazarotene—Application site rash—Estradiol—prostate cancer	0.00521	0.0252	CcSEcCtD
Tazarotene—Facial pain—Capecitabine—prostate cancer	0.00489	0.0236	CcSEcCtD
Tazarotene—Application site erythema—Estradiol—prostate cancer	0.00483	0.0233	CcSEcCtD
Tazarotene—Pain of skin—Estradiol—prostate cancer	0.00483	0.0233	CcSEcCtD
Tazarotene—Blood triglycerides increased—Abiraterone—prostate cancer	0.00477	0.0231	CcSEcCtD
Tazarotene—Localized exfoliation—Estradiol—prostate cancer	0.00422	0.0204	CcSEcCtD
Tazarotene—Application site irritation—Estradiol—prostate cancer	0.0041	0.0198	CcSEcCtD
Tazarotene—RARG—urethra—prostate cancer	0.00372	0.0865	CbGeAlD
Tazarotene—RARA—renal system—prostate cancer	0.00356	0.0828	CbGeAlD
Tazarotene—Acne—Estradiol valerate/Dienogest—prostate cancer	0.00319	0.0154	CcSEcCtD
Tazarotene—Skin exfoliation—Estramustine—prostate cancer	0.00308	0.0149	CcSEcCtD
Tazarotene—Localised oedema—Capecitabine—prostate cancer	0.00281	0.0136	CcSEcCtD
Tazarotene—RXRB—testis—prostate cancer	0.00276	0.0641	CbGeAlD
Tazarotene—RARA—bone marrow—prostate cancer	0.00269	0.0626	CbGeAlD
Tazarotene—Localized exfoliation—Capecitabine—prostate cancer	0.00263	0.0127	CcSEcCtD
Tazarotene—Inflammation—Degarelix—prostate cancer	0.00263	0.0127	CcSEcCtD
Tazarotene—RARG—testis—prostate cancer	0.00245	0.0569	CbGeAlD
Tazarotene—RARA—testis—prostate cancer	0.0023	0.0535	CbGeAlD
Tazarotene—RARB—lymph node—prostate cancer	0.00218	0.0506	CbGeAlD
Tazarotene—Dermatitis bullous—Flutamide—prostate cancer	0.00216	0.0104	CcSEcCtD
Tazarotene—Dry skin—Estramustine—prostate cancer	0.00214	0.0104	CcSEcCtD
Tazarotene—Swelling—Degarelix—prostate cancer	0.0021	0.0101	CcSEcCtD
Tazarotene—Acne—Ethinyl Estradiol—prostate cancer	0.00207	0.01	CcSEcCtD
Tazarotene—Blister—Conjugated Estrogens—prostate cancer	0.00197	0.00953	CcSEcCtD
Tazarotene—Dry skin—Nilutamide—prostate cancer	0.0019	0.00918	CcSEcCtD
Tazarotene—RARG—lymph node—prostate cancer	0.00178	0.0413	CbGeAlD
Tazarotene—Acne—Goserelin—prostate cancer	0.00171	0.00824	CcSEcCtD
Tazarotene—RARA—lymph node—prostate cancer	0.00167	0.0388	CbGeAlD
Tazarotene—Photosensitivity reaction—Flutamide—prostate cancer	0.00163	0.00787	CcSEcCtD
Tazarotene—Dry skin—Cabazitaxel—prostate cancer	0.0016	0.00773	CcSEcCtD
Tazarotene—Skin discolouration—Goserelin—prostate cancer	0.00159	0.00767	CcSEcCtD
Tazarotene—Leukoderma—Prednisone—prostate cancer	0.00149	0.00718	CcSEcCtD
Tazarotene—Inflammation—Conjugated Estrogens—prostate cancer	0.00147	0.00708	CcSEcCtD
Tazarotene—Oedema peripheral—Nilutamide—prostate cancer	0.00141	0.00683	CcSEcCtD
Tazarotene—CYP2C8—renal system—prostate cancer	0.00141	0.0328	CbGeAlD
Tazarotene—Eczema—Ethinyl Estradiol—prostate cancer	0.00141	0.0068	CcSEcCtD
Tazarotene—Oedema peripheral—Flutamide—prostate cancer	0.00141	0.0068	CcSEcCtD
Tazarotene—Sensitisation—Epirubicin—prostate cancer	0.00138	0.00668	CcSEcCtD
Tazarotene—Dry skin—Bicalutamide—prostate cancer	0.00137	0.00663	CcSEcCtD
Tazarotene—Acne—Estradiol—prostate cancer	0.00135	0.00653	CcSEcCtD
Tazarotene—Sensitisation—Doxorubicin—prostate cancer	0.00128	0.00619	CcSEcCtD
Tazarotene—Oedema peripheral—Degarelix—prostate cancer	0.00126	0.0061	CcSEcCtD
Tazarotene—Skin discolouration—Estradiol—prostate cancer	0.00126	0.00608	CcSEcCtD
Tazarotene—Erythema—Flutamide—prostate cancer	0.00124	0.00601	CcSEcCtD
Tazarotene—Hypertriglyceridaemia—Capecitabine—prostate cancer	0.00124	0.00597	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Docetaxel—prostate cancer	0.00123	0.00595	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Capecitabine—prostate cancer	0.00119	0.00576	CcSEcCtD
Tazarotene—Oedema peripheral—Cabazitaxel—prostate cancer	0.00119	0.00575	CcSEcCtD
Tazarotene—Swelling—Goserelin—prostate cancer	0.00118	0.0057	CcSEcCtD
Tazarotene—Inflammation—Estradiol—prostate cancer	0.00117	0.00567	CcSEcCtD
Tazarotene—Swelling—Conjugated Estrogens—prostate cancer	0.00117	0.00565	CcSEcCtD
Tazarotene—Leukoderma—Epirubicin—prostate cancer	0.00116	0.00562	CcSEcCtD
Tazarotene—Discomfort—Abiraterone—prostate cancer	0.00115	0.00556	CcSEcCtD
Tazarotene—Oedema—Estramustine—prostate cancer	0.00115	0.00555	CcSEcCtD
Tazarotene—Dermatitis contact—Estradiol—prostate cancer	0.00112	0.00543	CcSEcCtD
Tazarotene—Oedema—Abiraterone—prostate cancer	0.00112	0.00539	CcSEcCtD
Tazarotene—Erythema—Degarelix—prostate cancer	0.00112	0.00539	CcSEcCtD
Tazarotene—Hypertriglyceridaemia—Prednisone—prostate cancer	0.0011	0.00532	CcSEcCtD
Tazarotene—Oedema—Estrone—prostate cancer	0.0011	0.0053	CcSEcCtD
Tazarotene—Skin exfoliation—Estradiol—prostate cancer	0.00109	0.00525	CcSEcCtD
Tazarotene—Blood triglycerides increased—Capecitabine—prostate cancer	0.00108	0.00523	CcSEcCtD
Tazarotene—Dermatitis bullous—Conjugated Estrogens—prostate cancer	0.00108	0.00522	CcSEcCtD
Tazarotene—Leukoderma—Doxorubicin—prostate cancer	0.00108	0.0052	CcSEcCtD
Tazarotene—Burning sensation—Docetaxel—prostate cancer	0.00105	0.00509	CcSEcCtD
Tazarotene—Erythema—Cabazitaxel—prostate cancer	0.00105	0.00508	CcSEcCtD
Tazarotene—Discomfort—Nilutamide—prostate cancer	0.00105	0.00508	CcSEcCtD
Tazarotene—Discomfort—Flutamide—prostate cancer	0.00105	0.00505	CcSEcCtD
Tazarotene—Haemoglobin—Bicalutamide—prostate cancer	0.00104	0.00503	CcSEcCtD
Tazarotene—Haemorrhage—Bicalutamide—prostate cancer	0.00104	0.005	CcSEcCtD
Tazarotene—Oedema peripheral—Bicalutamide—prostate cancer	0.00102	0.00493	CcSEcCtD
Tazarotene—Oedema—Nilutamide—prostate cancer	0.00102	0.00492	CcSEcCtD
Tazarotene—Oedema—Flutamide—prostate cancer	0.00102	0.0049	CcSEcCtD
Tazarotene—Blister—Capecitabine—prostate cancer	0.000984	0.00475	CcSEcCtD
Tazarotene—Skin discolouration—Etoposide—prostate cancer	0.000976	0.00472	CcSEcCtD
Tazarotene—Blood triglycerides increased—Prednisone—prostate cancer	0.000965	0.00466	CcSEcCtD
Tazarotene—Oedema—Estradiol valerate/Dienogest—prostate cancer	0.000958	0.00463	CcSEcCtD
Tazarotene—Dry skin—Goserelin—prostate cancer	0.000955	0.00461	CcSEcCtD
Tazarotene—Discomfort—Degarelix—prostate cancer	0.000939	0.00453	CcSEcCtD
Tazarotene—Pain—Estrone—prostate cancer	0.000939	0.00453	CcSEcCtD
Tazarotene—Swelling—Estradiol—prostate cancer	0.000936	0.00452	CcSEcCtD
Tazarotene—Eczema—Estradiol—prostate cancer	0.000919	0.00444	CcSEcCtD
Tazarotene—CYP2C8—testis—prostate cancer	0.000913	0.0212	CbGeAlD
Tazarotene—Inflammation—Etoposide—prostate cancer	0.000909	0.00439	CcSEcCtD
Tazarotene—Discomfort—Cabazitaxel—prostate cancer	0.000884	0.00427	CcSEcCtD
Tazarotene—Haemoglobin—Ethinyl Estradiol—prostate cancer	0.00088	0.00425	CcSEcCtD
Tazarotene—Haemorrhage—Ethinyl Estradiol—prostate cancer	0.000876	0.00423	CcSEcCtD
Tazarotene—Swelling—Mitoxantrone—prostate cancer	0.000872	0.00421	CcSEcCtD
Tazarotene—Pain—Nilutamide—prostate cancer	0.000872	0.00421	CcSEcCtD
Tazarotene—Oedema—Cabazitaxel—prostate cancer	0.000858	0.00414	CcSEcCtD
Tazarotene—Skin exfoliation—Etoposide—prostate cancer	0.000842	0.00407	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Epirubicin—prostate cancer	0.000831	0.00401	CcSEcCtD
Tazarotene—Photosensitivity reaction—Goserelin—prostate cancer	0.000822	0.00397	CcSEcCtD
Tazarotene—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000819	0.00396	CcSEcCtD
Tazarotene—Pruritus—Estramustine—prostate cancer	0.000813	0.00393	CcSEcCtD
Tazarotene—Skin discolouration—Capecitabine—prostate cancer	0.000786	0.00379	CcSEcCtD
Tazarotene—Pain—Degarelix—prostate cancer	0.000779	0.00376	CcSEcCtD
Tazarotene—Pruritus—Estrone—prostate cancer	0.000777	0.00375	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Doxorubicin—prostate cancer	0.000769	0.00371	CcSEcCtD
Tazarotene—Dry skin—Estradiol—prostate cancer	0.000757	0.00366	CcSEcCtD
Tazarotene—Inflammation—Docetaxel—prostate cancer	0.000756	0.00365	CcSEcCtD
Tazarotene—Acne—Prednisone—prostate cancer	0.000751	0.00363	CcSEcCtD
Tazarotene—Oedema—Bicalutamide—prostate cancer	0.000736	0.00356	CcSEcCtD
Tazarotene—Pain—Cabazitaxel—prostate cancer	0.000734	0.00354	CcSEcCtD
Tazarotene—Inflammation—Capecitabine—prostate cancer	0.000731	0.00353	CcSEcCtD
Tazarotene—Swelling—Etoposide—prostate cancer	0.000726	0.0035	CcSEcCtD
Tazarotene—Rash—Estramustine—prostate cancer	0.000725	0.0035	CcSEcCtD
Tazarotene—Haemoglobin—Goserelin—prostate cancer	0.000724	0.0035	CcSEcCtD
Tazarotene—Dermatitis—Estramustine—prostate cancer	0.000724	0.0035	CcSEcCtD
Tazarotene—Pruritus—Nilutamide—prostate cancer	0.000721	0.00348	CcSEcCtD
Tazarotene—Haemorrhage—Goserelin—prostate cancer	0.000721	0.00348	CcSEcCtD
Tazarotene—Pruritus—Flutamide—prostate cancer	0.000718	0.00347	CcSEcCtD
Tazarotene—Burning sensation—Epirubicin—prostate cancer	0.000711	0.00344	CcSEcCtD
Tazarotene—Oedema peripheral—Goserelin—prostate cancer	0.00071	0.00343	CcSEcCtD
Tazarotene—Rash—Abiraterone—prostate cancer	0.000704	0.0034	CcSEcCtD
Tazarotene—Oedema peripheral—Conjugated Estrogens—prostate cancer	0.000703	0.0034	CcSEcCtD
Tazarotene—Dermatitis—Abiraterone—prostate cancer	0.000703	0.0034	CcSEcCtD
Tazarotene—Skin exfoliation—Docetaxel—prostate cancer	0.0007	0.00338	CcSEcCtD
Tazarotene—Rash—Estrone—prostate cancer	0.000692	0.00334	CcSEcCtD
Tazarotene—Dermatitis—Estrone—prostate cancer	0.000692	0.00334	CcSEcCtD
Tazarotene—Blister—Epirubicin—prostate cancer	0.000686	0.00331	CcSEcCtD
Tazarotene—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000678	0.00327	CcSEcCtD
Tazarotene—Skin exfoliation—Capecitabine—prostate cancer	0.000677	0.00327	CcSEcCtD
Tazarotene—Burning sensation—Doxorubicin—prostate cancer	0.000658	0.00318	CcSEcCtD
Tazarotene—Photosensitivity reaction—Estradiol—prostate cancer	0.000652	0.00315	CcSEcCtD
Tazarotene—Pruritus—Degarelix—prostate cancer	0.000644	0.00311	CcSEcCtD
Tazarotene—Rash—Nilutamide—prostate cancer	0.000643	0.00311	CcSEcCtD
Tazarotene—Dermatitis—Nilutamide—prostate cancer	0.000642	0.0031	CcSEcCtD
Tazarotene—Discomfort—Ethinyl Estradiol—prostate cancer	0.000641	0.0031	CcSEcCtD
Tazarotene—Rash—Flutamide—prostate cancer	0.00064	0.00309	CcSEcCtD
Tazarotene—Dermatitis—Flutamide—prostate cancer	0.000639	0.00309	CcSEcCtD
Tazarotene—Blister—Doxorubicin—prostate cancer	0.000635	0.00306	CcSEcCtD
Tazarotene—Pain—Bicalutamide—prostate cancer	0.000629	0.00304	CcSEcCtD
Tazarotene—Erythema—Goserelin—prostate cancer	0.000627	0.00303	CcSEcCtD
Tazarotene—Oedema—Ethinyl Estradiol—prostate cancer	0.000622	0.00301	CcSEcCtD
Tazarotene—Erythema—Conjugated Estrogens—prostate cancer	0.000621	0.003	CcSEcCtD
Tazarotene—Stinging—Epirubicin—prostate cancer	0.00061	0.00295	CcSEcCtD
Tazarotene—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000604	0.00292	CcSEcCtD
Tazarotene—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000604	0.00291	CcSEcCtD
Tazarotene—Skin exfoliation—Prednisone—prostate cancer	0.000603	0.00291	CcSEcCtD
Tazarotene—Swelling—Docetaxel—prostate cancer	0.000603	0.00291	CcSEcCtD
Tazarotene—Swelling—Capecitabine—prostate cancer	0.000584	0.00282	CcSEcCtD
Tazarotene—Rash—Degarelix—prostate cancer	0.000574	0.00277	CcSEcCtD
Tazarotene—Haemoglobin—Estradiol—prostate cancer	0.000574	0.00277	CcSEcCtD
Tazarotene—Dermatitis—Degarelix—prostate cancer	0.000574	0.00277	CcSEcCtD
Tazarotene—Haemorrhage—Estradiol—prostate cancer	0.000571	0.00276	CcSEcCtD
Tazarotene—Stinging—Doxorubicin—prostate cancer	0.000565	0.00273	CcSEcCtD
Tazarotene—Oedema peripheral—Estradiol—prostate cancer	0.000563	0.00272	CcSEcCtD
Tazarotene—Dermatitis bullous—Docetaxel—prostate cancer	0.000557	0.00269	CcSEcCtD
Tazarotene—Skin discolouration—Epirubicin—prostate cancer	0.000547	0.00264	CcSEcCtD
Tazarotene—Dermatitis bullous—Capecitabine—prostate cancer	0.000539	0.0026	CcSEcCtD
Tazarotene—Haemoglobin—Mitoxantrone—prostate cancer	0.000535	0.00258	CcSEcCtD
Tazarotene—Haemorrhage—Mitoxantrone—prostate cancer	0.000532	0.00257	CcSEcCtD
Tazarotene—Discomfort—Goserelin—prostate cancer	0.000528	0.00255	CcSEcCtD
Tazarotene—Pruritus—Bicalutamide—prostate cancer	0.000521	0.00252	CcSEcCtD
Tazarotene—Oedema—Goserelin—prostate cancer	0.000512	0.00247	CcSEcCtD
Tazarotene—Inflammation—Epirubicin—prostate cancer	0.00051	0.00246	CcSEcCtD
Tazarotene—Oedema—Conjugated Estrogens—prostate cancer	0.000507	0.00245	CcSEcCtD
Tazarotene—Skin discolouration—Doxorubicin—prostate cancer	0.000506	0.00245	CcSEcCtD
Tazarotene—Erythema—Estradiol—prostate cancer	0.000497	0.0024	CcSEcCtD
Tazarotene—Dermatitis contact—Epirubicin—prostate cancer	0.000489	0.00236	CcSEcCtD
Tazarotene—Dry skin—Docetaxel—prostate cancer	0.000488	0.00236	CcSEcCtD
Tazarotene—Dry skin—Capecitabine—prostate cancer	0.000472	0.00228	CcSEcCtD
Tazarotene—Skin exfoliation—Epirubicin—prostate cancer	0.000472	0.00228	CcSEcCtD
Tazarotene—Inflammation—Doxorubicin—prostate cancer	0.000472	0.00228	CcSEcCtD
Tazarotene—Rash—Bicalutamide—prostate cancer	0.000464	0.00224	CcSEcCtD
Tazarotene—Dermatitis—Bicalutamide—prostate cancer	0.000464	0.00224	CcSEcCtD
Tazarotene—Erythema—Mitoxantrone—prostate cancer	0.000463	0.00224	CcSEcCtD
Tazarotene—Dermatitis contact—Doxorubicin—prostate cancer	0.000452	0.00218	CcSEcCtD
Tazarotene—Pruritus—Ethinyl Estradiol—prostate cancer	0.00044	0.00213	CcSEcCtD
Tazarotene—Pain—Goserelin—prostate cancer	0.000438	0.00211	CcSEcCtD
Tazarotene—Skin exfoliation—Doxorubicin—prostate cancer	0.000437	0.00211	CcSEcCtD
Tazarotene—Pain—Conjugated Estrogens—prostate cancer	0.000434	0.00209	CcSEcCtD
Tazarotene—Dry skin—Prednisone—prostate cancer	0.000421	0.00203	CcSEcCtD
Tazarotene—Discomfort—Estradiol—prostate cancer	0.000418	0.00202	CcSEcCtD
Tazarotene—Photosensitivity reaction—Capecitabine—prostate cancer	0.000406	0.00196	CcSEcCtD
Tazarotene—Oedema—Estradiol—prostate cancer	0.000406	0.00196	CcSEcCtD
Tazarotene—Eczema—Epirubicin—prostate cancer	0.000399	0.00193	CcSEcCtD
Tazarotene—Rash—Ethinyl Estradiol—prostate cancer	0.000392	0.00189	CcSEcCtD
Tazarotene—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000392	0.00189	CcSEcCtD
Tazarotene—Discomfort—Mitoxantrone—prostate cancer	0.00039	0.00188	CcSEcCtD
Tazarotene—Oedema—Mitoxantrone—prostate cancer	0.000378	0.00183	CcSEcCtD
Tazarotene—Dermatitis bullous—Epirubicin—prostate cancer	0.000375	0.00181	CcSEcCtD
Tazarotene—Haemoglobin—Docetaxel—prostate cancer	0.00037	0.00179	CcSEcCtD
Tazarotene—Eczema—Doxorubicin—prostate cancer	0.000369	0.00178	CcSEcCtD
Tazarotene—Haemorrhage—Docetaxel—prostate cancer	0.000368	0.00178	CcSEcCtD
Tazarotene—Oedema peripheral—Docetaxel—prostate cancer	0.000363	0.00175	CcSEcCtD
Tazarotene—Pruritus—Goserelin—prostate cancer	0.000362	0.00175	CcSEcCtD
Tazarotene—Pruritus—Conjugated Estrogens—prostate cancer	0.000359	0.00173	CcSEcCtD
Tazarotene—Haemoglobin—Capecitabine—prostate cancer	0.000358	0.00173	CcSEcCtD
Tazarotene—Haemorrhage—Capecitabine—prostate cancer	0.000356	0.00172	CcSEcCtD
Tazarotene—Oedema peripheral—Capecitabine—prostate cancer	0.000351	0.0017	CcSEcCtD
Tazarotene—Dermatitis bullous—Doxorubicin—prostate cancer	0.000347	0.00168	CcSEcCtD
Tazarotene—Pain—Estradiol—prostate cancer	0.000347	0.00168	CcSEcCtD
Tazarotene—Dry skin—Epirubicin—prostate cancer	0.000329	0.00159	CcSEcCtD
Tazarotene—Discomfort—Etoposide—prostate cancer	0.000324	0.00157	CcSEcCtD
Tazarotene—Pain—Mitoxantrone—prostate cancer	0.000323	0.00156	CcSEcCtD
Tazarotene—Rash—Goserelin—prostate cancer	0.000323	0.00156	CcSEcCtD
Tazarotene—Dermatitis—Goserelin—prostate cancer	0.000323	0.00156	CcSEcCtD
Tazarotene—Erythema—Docetaxel—prostate cancer	0.00032	0.00155	CcSEcCtD
Tazarotene—Rash—Conjugated Estrogens—prostate cancer	0.00032	0.00154	CcSEcCtD
Tazarotene—Dermatitis—Conjugated Estrogens—prostate cancer	0.00032	0.00154	CcSEcCtD
Tazarotene—Haemoglobin—Prednisone—prostate cancer	0.000319	0.00154	CcSEcCtD
Tazarotene—Haemorrhage—Prednisone—prostate cancer	0.000317	0.00153	CcSEcCtD
Tazarotene—Erythema—Capecitabine—prostate cancer	0.00031	0.0015	CcSEcCtD
Tazarotene—Dry skin—Doxorubicin—prostate cancer	0.000304	0.00147	CcSEcCtD
Tazarotene—Pruritus—Estradiol—prostate cancer	0.000287	0.00139	CcSEcCtD
Tazarotene—Photosensitivity reaction—Epirubicin—prostate cancer	0.000283	0.00137	CcSEcCtD
Tazarotene—Erythema—Prednisone—prostate cancer	0.000276	0.00133	CcSEcCtD
Tazarotene—Pain—Etoposide—prostate cancer	0.000269	0.0013	CcSEcCtD
Tazarotene—Photosensitivity reaction—Doxorubicin—prostate cancer	0.000262	0.00127	CcSEcCtD
Tazarotene—Oedema—Docetaxel—prostate cancer	0.000261	0.00126	CcSEcCtD
Tazarotene—Discomfort—Capecitabine—prostate cancer	0.000261	0.00126	CcSEcCtD
Tazarotene—Rash—Estradiol—prostate cancer	0.000256	0.00124	CcSEcCtD
Tazarotene—Dermatitis—Estradiol—prostate cancer	0.000256	0.00124	CcSEcCtD
Tazarotene—Oedema—Capecitabine—prostate cancer	0.000253	0.00122	CcSEcCtD
Tazarotene—Haemoglobin—Epirubicin—prostate cancer	0.000249	0.00121	CcSEcCtD
Tazarotene—Haemorrhage—Epirubicin—prostate cancer	0.000248	0.0012	CcSEcCtD
Tazarotene—Oedema peripheral—Epirubicin—prostate cancer	0.000245	0.00118	CcSEcCtD
Tazarotene—Rash—Mitoxantrone—prostate cancer	0.000238	0.00115	CcSEcCtD
Tazarotene—Dermatitis—Mitoxantrone—prostate cancer	0.000238	0.00115	CcSEcCtD
Tazarotene—Discomfort—Prednisone—prostate cancer	0.000232	0.00112	CcSEcCtD
Tazarotene—Haemoglobin—Doxorubicin—prostate cancer	0.000231	0.00111	CcSEcCtD
Tazarotene—Haemorrhage—Doxorubicin—prostate cancer	0.00023	0.00111	CcSEcCtD
Tazarotene—Oedema peripheral—Doxorubicin—prostate cancer	0.000226	0.00109	CcSEcCtD
Tazarotene—Oedema—Prednisone—prostate cancer	0.000225	0.00109	CcSEcCtD
Tazarotene—Pain—Docetaxel—prostate cancer	0.000224	0.00108	CcSEcCtD
Tazarotene—Pruritus—Etoposide—prostate cancer	0.000223	0.00108	CcSEcCtD
Tazarotene—Pain—Capecitabine—prostate cancer	0.000216	0.00105	CcSEcCtD
Tazarotene—Erythema—Epirubicin—prostate cancer	0.000216	0.00104	CcSEcCtD
Tazarotene—Erythema—Doxorubicin—prostate cancer	0.0002	0.000966	CcSEcCtD
Tazarotene—Rash—Etoposide—prostate cancer	0.000198	0.000958	CcSEcCtD
Tazarotene—Dermatitis—Etoposide—prostate cancer	0.000198	0.000957	CcSEcCtD
Tazarotene—Pruritus—Docetaxel—prostate cancer	0.000185	0.000893	CcSEcCtD
Tazarotene—Discomfort—Epirubicin—prostate cancer	0.000182	0.000878	CcSEcCtD
Tazarotene—Pruritus—Capecitabine—prostate cancer	0.000179	0.000865	CcSEcCtD
Tazarotene—Oedema—Epirubicin—prostate cancer	0.000176	0.000852	CcSEcCtD
Tazarotene—Discomfort—Doxorubicin—prostate cancer	0.000168	0.000812	CcSEcCtD
Tazarotene—Rash—Docetaxel—prostate cancer	0.000165	0.000796	CcSEcCtD
Tazarotene—Dermatitis—Docetaxel—prostate cancer	0.000165	0.000796	CcSEcCtD
Tazarotene—Oedema—Doxorubicin—prostate cancer	0.000163	0.000788	CcSEcCtD
Tazarotene—Rash—Capecitabine—prostate cancer	0.00016	0.000771	CcSEcCtD
Tazarotene—Pruritus—Prednisone—prostate cancer	0.00016	0.000771	CcSEcCtD
Tazarotene—Dermatitis—Capecitabine—prostate cancer	0.000159	0.00077	CcSEcCtD
Tazarotene—Pain—Epirubicin—prostate cancer	0.000151	0.000728	CcSEcCtD
Tazarotene—Rash—Prednisone—prostate cancer	0.000142	0.000687	CcSEcCtD
Tazarotene—Dermatitis—Prednisone—prostate cancer	0.000142	0.000686	CcSEcCtD
Tazarotene—Pain—Doxorubicin—prostate cancer	0.00014	0.000674	CcSEcCtD
Tazarotene—Pruritus—Epirubicin—prostate cancer	0.000125	0.000603	CcSEcCtD
Tazarotene—Pruritus—Doxorubicin—prostate cancer	0.000115	0.000558	CcSEcCtD
Tazarotene—Rash—Epirubicin—prostate cancer	0.000111	0.000537	CcSEcCtD
Tazarotene—Dermatitis—Epirubicin—prostate cancer	0.000111	0.000537	CcSEcCtD
Tazarotene—Rash—Doxorubicin—prostate cancer	0.000103	0.000497	CcSEcCtD
Tazarotene—Dermatitis—Doxorubicin—prostate cancer	0.000103	0.000496	CcSEcCtD
Tazarotene—RARA—Gene Expression—RPS19—prostate cancer	6.48e-05	0.000243	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—HSPA1A—prostate cancer	6.47e-05	0.000243	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR2—prostate cancer	6.47e-05	0.000243	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—DNMT1—prostate cancer	6.46e-05	0.000243	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—CREBBP—prostate cancer	6.4e-05	0.00024	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NCOA2—prostate cancer	6.34e-05	0.000238	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HSD17B1—prostate cancer	6.32e-05	0.000237	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	6.28e-05	0.000236	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—EZH2—prostate cancer	6.26e-05	0.000235	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	6.23e-05	0.000234	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—DNMT1—prostate cancer	6.19e-05	0.000232	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—DNMT1—prostate cancer	6.19e-05	0.000232	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP2E1—prostate cancer	6.16e-05	0.000231	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—CREBBP—prostate cancer	6.14e-05	0.00023	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—CREBBP—prostate cancer	6.14e-05	0.00023	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PARP1—prostate cancer	6.13e-05	0.00023	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NCOA2—prostate cancer	6.08e-05	0.000228	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NCOA2—prostate cancer	6.08e-05	0.000228	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP2E1—prostate cancer	6.07e-05	0.000228	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	6.02e-05	0.000226	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—SERPINE1—prostate cancer	6.01e-05	0.000225	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EZH2—prostate cancer	6e-05	0.000225	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EZH2—prostate cancer	6e-05	0.000225	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NCOA1—prostate cancer	5.96e-05	0.000224	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP3A4—prostate cancer	5.94e-05	0.000223	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PARP1—prostate cancer	5.87e-05	0.00022	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PARP1—prostate cancer	5.87e-05	0.00022	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP3A4—prostate cancer	5.86e-05	0.00022	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP1B1—prostate cancer	5.84e-05	0.000219	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—HSPA1A—prostate cancer	5.8e-05	0.000218	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR2—prostate cancer	5.8e-05	0.000218	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP1B1—prostate cancer	5.76e-05	0.000216	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—SERPINE1—prostate cancer	5.76e-05	0.000216	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—SERPINE1—prostate cancer	5.76e-05	0.000216	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—AR—prostate cancer	5.71e-05	0.000214	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—RXRA—prostate cancer	5.67e-05	0.000213	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GGT1—prostate cancer	5.65e-05	0.000212	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—prostate cancer	5.63e-05	0.000211	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—NCOA1—prostate cancer	5.57e-05	0.000209	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—HSPA1A—prostate cancer	5.56e-05	0.000209	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—HSPA1A—prostate cancer	5.56e-05	0.000209	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR2—prostate cancer	5.56e-05	0.000209	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR2—prostate cancer	5.56e-05	0.000209	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP19A1—prostate cancer	5.49e-05	0.000206	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP19A1—prostate cancer	5.41e-05	0.000203	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NCOA1—prostate cancer	5.34e-05	0.000201	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	5.31e-05	0.000199	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—RXRA—prostate cancer	5.3e-05	0.000199	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	5.29e-05	0.000199	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SIRT1—prostate cancer	5.21e-05	0.000195	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	5.15e-05	0.000193	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—VDR—prostate cancer	5.13e-05	0.000193	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NCOA1—prostate cancer	5.12e-05	0.000192	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—AR—prostate cancer	5.12e-05	0.000192	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NCOA1—prostate cancer	5.12e-05	0.000192	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—COMT—prostate cancer	5.1e-05	0.000192	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	5.09e-05	0.000191	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—RXRA—prostate cancer	5.08e-05	0.000191	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTP1—prostate cancer	5.08e-05	0.000191	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—COMT—prostate cancer	5.03e-05	0.000189	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	5.02e-05	0.000188	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTP1—prostate cancer	5.01e-05	0.000188	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—AR—prostate cancer	4.91e-05	0.000184	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—AR—prostate cancer	4.91e-05	0.000184	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—RXRA—prostate cancer	4.87e-05	0.000183	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—RXRA—prostate cancer	4.87e-05	0.000183	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	4.79e-05	0.00018	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	4.79e-05	0.00018	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ERCC2—prostate cancer	4.69e-05	0.000176	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SIRT1—prostate cancer	4.67e-05	0.000175	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTM1—prostate cancer	4.67e-05	0.000175	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NR3C1—prostate cancer	4.62e-05	0.000173	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—VDR—prostate cancer	4.6e-05	0.000173	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTM1—prostate cancer	4.6e-05	0.000173	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SIRT1—prostate cancer	4.48e-05	0.000168	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SIRT1—prostate cancer	4.48e-05	0.000168	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP1A1—prostate cancer	4.42e-05	0.000166	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—VDR—prostate cancer	4.41e-05	0.000166	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—VDR—prostate cancer	4.41e-05	0.000166	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HAO1—prostate cancer	4.37e-05	0.000164	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP1A1—prostate cancer	4.36e-05	0.000164	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PPARA—prostate cancer	4.33e-05	0.000162	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—MYC—prostate cancer	4.24e-05	0.000159	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ERCC2—prostate cancer	4.21e-05	0.000158	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NR3C1—prostate cancer	4.14e-05	0.000156	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	4.07e-05	0.000153	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ERCC2—prostate cancer	4.04e-05	0.000152	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ERCC2—prostate cancer	4.04e-05	0.000152	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NR3C1—prostate cancer	3.97e-05	0.000149	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NR3C1—prostate cancer	3.97e-05	0.000149	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR1—prostate cancer	3.92e-05	0.000147	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	3.9e-05	0.000146	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PPARA—prostate cancer	3.88e-05	0.000146	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—MYC—prostate cancer	3.8e-05	0.000143	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	3.76e-05	0.000141	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PPARA—prostate cancer	3.72e-05	0.00014	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PPARA—prostate cancer	3.72e-05	0.00014	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—MYC—prostate cancer	3.64e-05	0.000137	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—MYC—prostate cancer	3.64e-05	0.000137	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	3.63e-05	0.000136	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CBR1—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADI1—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CSAD—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TST—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PSAT1—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GRHL1—prostate cancer	3.56e-05	0.000134	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR1—prostate cancer	3.52e-05	0.000132	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	3.48e-05	0.000131	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—CREBBP—prostate cancer	3.44e-05	0.000129	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	3.41e-05	0.000128	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR1—prostate cancer	3.37e-05	0.000127	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR1—prostate cancer	3.37e-05	0.000127	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GRHPR—prostate cancer	3.31e-05	0.000124	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UGT2B17—prostate cancer	3.31e-05	0.000124	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UGT2B15—prostate cancer	3.31e-05	0.000124	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CKMT2—prostate cancer	3.31e-05	0.000124	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	3.23e-05	0.000121	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SERPINE1—prostate cancer	3.22e-05	0.000121	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—MED12—prostate cancer	3.18e-05	0.000119	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PGAM2—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTM3—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RFK—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SULT2B1—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MBTPS1—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AOX1—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NAGLU—prostate cancer	3.11e-05	0.000117	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—CREBBP—prostate cancer	3.08e-05	0.000116	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	3.04e-05	0.000114	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CREBBP—prostate cancer	2.96e-05	0.000111	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—CREBBP—prostate cancer	2.96e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AMACR—prostate cancer	2.95e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP3A43—prostate cancer	2.95e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NAT1—prostate cancer	2.95e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SRD5A2—prostate cancer	2.95e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—DEGS1—prostate cancer	2.95e-05	0.000111	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	2.9e-05	0.000109	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SERPINE1—prostate cancer	2.89e-05	0.000109	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	2.88e-05	0.000108	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HSD17B1—prostate cancer	2.81e-05	0.000106	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	2.81e-05	0.000106	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SERPINE1—prostate cancer	2.77e-05	0.000104	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SERPINE1—prostate cancer	2.77e-05	0.000104	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	2.71e-05	0.000102	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	2.69e-05	0.000101	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	2.66e-05	0.0001	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	2.54e-05	9.53e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HPGD—prostate cancer	2.51e-05	9.41e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—B4GALT4—prostate cancer	2.51e-05	9.41e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TNFRSF21—prostate cancer	2.36e-05	8.85e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP7B1—prostate cancer	2.29e-05	8.61e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MTAP—prostate cancer	2.29e-05	8.61e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.24e-05	8.41e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SULT1E1—prostate cancer	2.24e-05	8.39e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SRD5A1—prostate cancer	2.24e-05	8.39e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.17e-05	8.15e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.14e-05	8.03e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HSD17B3—prostate cancer	2.13e-05	8e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ACSL4—prostate cancer	2.13e-05	8e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.11e-05	7.91e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PHGDH—prostate cancer	2.04e-05	7.67e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UMPS—prostate cancer	2.04e-05	7.67e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ARG2—prostate cancer	2.04e-05	7.67e-05	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—MYC—prostate cancer	2.04e-05	7.66e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.03e-05	7.63e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—LDHB—prostate cancer	2e-05	7.52e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP3A5—prostate cancer	1.97e-05	7.39e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PDHA1—prostate cancer	1.9e-05	7.13e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTA3—prostate cancer	1.9e-05	7.13e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TCN2—prostate cancer	1.9e-05	7.13e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UCP3—prostate cancer	1.9e-05	7.13e-05	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—MYC—prostate cancer	1.83e-05	6.87e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC22A3—prostate cancer	1.81e-05	6.81e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HSD3B1—prostate cancer	1.81e-05	6.81e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.76e-05	6.6e-05	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—MYC—prostate cancer	1.75e-05	6.58e-05	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—MYC—prostate cancer	1.75e-05	6.58e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TBXAS1—prostate cancer	1.74e-05	6.52e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTA4—prostate cancer	1.74e-05	6.52e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.7e-05	6.38e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTA2—prostate cancer	1.69e-05	6.36e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SULT1A1—prostate cancer	1.67e-05	6.28e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ABCG5—prostate cancer	1.67e-05	6.28e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTA1—prostate cancer	1.63e-05	6.13e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HSD3B2—prostate cancer	1.62e-05	6.07e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTO1—prostate cancer	1.62e-05	6.07e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NAT2—prostate cancer	1.62e-05	6.07e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.55e-05	5.83e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—LRP2—prostate cancer	1.55e-05	5.82e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PLCB2—prostate cancer	1.55e-05	5.82e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2C18—prostate cancer	1.55e-05	5.82e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—P4HB—prostate cancer	1.52e-05	5.7e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC22A1—prostate cancer	1.48e-05	5.55e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.46e-05	5.48e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SULT2A1—prostate cancer	1.44e-05	5.41e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MED12—prostate cancer	1.42e-05	5.32e-05	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—AKT1—prostate cancer	1.41e-05	5.31e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GNG5—prostate cancer	1.41e-05	5.28e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NCOA3—prostate cancer	1.35e-05	5.08e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.33e-05	4.99e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HPGDS—prostate cancer	1.29e-05	4.85e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2C19—prostate cancer	1.28e-05	4.82e-05	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—AKT1—prostate cancer	1.27e-05	4.76e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTT1—prostate cancer	1.25e-05	4.7e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ACHE—prostate cancer	1.25e-05	4.7e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2A6—prostate cancer	1.24e-05	4.65e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.23e-05	4.63e-05	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—AKT1—prostate cancer	1.22e-05	4.57e-05	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—AKT1—prostate cancer	1.22e-05	4.57e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKR1C3—prostate cancer	1.2e-05	4.52e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PRKACB—prostate cancer	1.2e-05	4.5e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP17A1—prostate cancer	1.19e-05	4.45e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.17e-05	4.39e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NCOA2—prostate cancer	1.13e-05	4.24e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC5A5—prostate cancer	1.08e-05	4.05e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2E1—prostate cancer	1.05e-05	3.95e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NQO1—prostate cancer	1.04e-05	3.91e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TH—prostate cancer	1.03e-05	3.85e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.02e-05	3.83e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP3A4—prostate cancer	1.02e-05	3.81e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.01e-05	3.79e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP1B1—prostate cancer	9.98e-06	3.75e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GGT1—prostate cancer	9.67e-06	3.63e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NCOA1—prostate cancer	9.52e-06	3.57e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP19A1—prostate cancer	9.39e-06	3.52e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RXRA—prostate cancer	9.06e-06	3.4e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	8.81e-06	3.31e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—COMT—prostate cancer	8.73e-06	3.28e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTP1—prostate cancer	8.69e-06	3.26e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ITPR1—prostate cancer	8.55e-06	3.21e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.4e-06	3.15e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TYMS—prostate cancer	8.07e-06	3.03e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTM1—prostate cancer	7.98e-06	3e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—LPL—prostate cancer	7.83e-06	2.94e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP1A1—prostate cancer	7.57e-06	2.84e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ERCC2—prostate cancer	7.5e-06	2.82e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MTHFR—prostate cancer	7.05e-06	2.65e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PPARA—prostate cancer	6.92e-06	2.6e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CAV1—prostate cancer	6.51e-06	2.44e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.22e-06	2.33e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CG—prostate cancer	5.93e-06	2.22e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—INS—prostate cancer	5.61e-06	2.11e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CREBBP—prostate cancer	5.5e-06	2.06e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CD—prostate cancer	5.21e-06	1.96e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NOS3—prostate cancer	4.92e-06	1.85e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CB—prostate cancer	4.54e-06	1.7e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS2—prostate cancer	4.5e-06	1.69e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTEN—prostate cancer	3.92e-06	1.47e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—EP300—prostate cancer	3.74e-06	1.4e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CA—prostate cancer	2.77e-06	1.04e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKT1—prostate cancer	2.26e-06	8.49e-06	CbGpPWpGaD
